Skip to main content

Table 1 Cost effectiveness model overview

From: Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia

Aspect

Details

Analytical method

Markov state transition model incorporating a decision tree

Software used

Microsoft Excel 2010

Model perspective

UK NHS

Time horizon

1 year

Cycle length

4 weeks

Patient population

Men with LUTS/BPH who have moderate-to-severe storage symptoms (≥8 micturitions/day and ≥2 urgency episodes/day*) and voiding symptoms

Treatments

Once-daily FDC tablet of solifenacin 6 mg plus TOCAS 0.4 mg

Tolterodine ER 4 mg plus tamsulosin 0.4 mg daily, given concomitantly

Outcomes

Total treatment costs

Quality adjusted life years

Incremental cost-effectiveness ratio

  1. *Patient Perception of Intensity of Urgency Scale, grade 3 or 4.
  2. BPH, benign prostatic hyperplasia; ER, extended release; FDC, fixed-dose combination; LUTS, lower urinary tract symptoms; TOCAS, oral controlled absorption system (OCASâ„¢) formulation of tamsulosin.